Zurich (awp) – Novartis, dismissed by the United States Court of Appeals on the validity of a patent on a dosage of its sales engine Gilenya (fingolimod), plans to bring the case back to the Supreme Court. For some time now, the Rhine multinational has made the achievement of its financial objectives conditional on the absence of the launch of generic versions of this treatment for multiple sclerosis.
The marketing this year of a substitute version could negatively affect sales by nearly a third of a billion dollars, the laboratory warns in a press release on Wednesday. Gilenya earned Novartis 2.79 billion Swiss francs last year.
jh/ol